• US Nuclear and Grapheton Brain Implants to Help Immobilized Patients

    US Nuclear and Grapheton Brain Implants to Help Immobilized Patients

    Los Angeles, CA.  November 2, 2020 – US Nuclear (OTC: UCLE) and Grapheton’s implantable bioelectronic sensors can be used to help treat millions of people worldwide suffering from mobility problems.  Neuroscientists stress there is a large unmet demand to develop implantable sensors and the artificial intelligence required to translate the brain signals into specific commands or actions. As many as 500,000 people worldwide suffer spinal cord injuries every year and approximately 1.7% of the U.S. population or 5.4 million people suffer from some form of paralysis. Furthermore, COVID-19 has caused an increase in the number of strokes, especially among younger individuals.
    (more…)

  • US Nuclear Secures Its Position at Bioelectronics Startup Grapheton

    US Nuclear Secures Its Position at Bioelectronics Startup Grapheton

    Los Angeles, CA.  October 19, 2020 – In addition to US Nuclear’s (OTC: UCLE) 40% stake in Grapheton, CEO Robert Goldstein has recently taken a seat on Grapheton’s board of directors and will now serve as Chief Strategy Officer. As Chief Strategy Officer for Grapheton, Robert Goldstein will help the business become a leader in the new field of bioelectronics and will cement the partnership between US Nuclear and Grapheton.

    Grapheton’s unique, patented bioelectronic implants lead the world in bio-compatibility and longevity. Bioelectronics is becoming popular among researchers and doctors, and the bioelectronics market is likely to experience tremendous growth in the near future. In recent years, there have been numerous breakthroughs using bioelectronics technology. A notable example, bioelectronic devices have been researched and used in clinical trials to treat rheumatoid arthritis and Crohn’s disease by electrically stimulating the vagus nerve to control inflammation and the immune response.

    Bioelectronics has the potential to become a vital branch of medical treatment. Medical care, in general, has made many advances in recent years, but there are a great many diseases, conditions, injuries, and remaining unmet patient needs that still need to be urgently addressed.
    (more…)

  • Tritium Monitor Market Soars Due to Construction of $20+ Billion ITER Fusion Energy Project

    Tritium Monitor Market Soars Due to Construction of $20+ Billion ITER Fusion Energy Project

    Los Angeles, CA.  October 6, 2020 – As the construction of the huge ITER tokamak grows towards completion, the tritium monitoring market is soaring. As the world leader in quality tritium monitoring instrumentation, US Nuclear’s (OTC: UCLE) Overhoff division is poised to capture a large portion of this business.

    The ITER fusion project seeks to develop a major new source of electric power to help supply the world’s fast-growing appetite for dependable, 24/7 electric power. Fusion is fueled by tritium and deuterium, which are both isotopes of hydrogen.  Tritium is in short supply and ITER will fully deplete the global inventory. ITER is a $20+ billion international scientific and engineering project jointly funded by the European UnionChinaIndiaJapanRussiaSouth Korea, and the United States.

    (more…)

  • US Nuclear Corp. Announces Second Quarter 2020 Results

    US Nuclear Corp. Announces Second Quarter 2020 Results

    Los Angeles, CA. September 24, 2020 – US Nuclear Corp. (OTC: UCLE), a leading manufacturer of advanced radiation, chemical, and biological detection and UAV instrumentation, recently announced the financial results for the second quarter ended June 30, 2020.

      • Sales for the three months ended June 30, 2020, were $302,201 compared to $1,530,523 for the same period in 2019
      • Decrease in sales due to the impact of COVID-19 on the company and customers
      • Overhoff operating branch was temporarily closed 3 months to allow employees to safely isolate themselves at home
      • Employee work hours reduced by half to help mitigate COVID-19 exposure and transmission
      • Selling, general, and administrative expense were $346,203 compared to $1,246,309 for the same period in 2019, the decrease of $900,106 or 72.2% was due to careful money management and lower stock-based compensation
      • Net loss of $145,117 due to impact of COVID-19
      • $841,000 available cash in the bank with approximately $850,000 of backlogged orders

    (more…)

  • Making Our COVID Survivors Whole Again By Solving Yet Another Desperate Shortage

    Making Our COVID Survivors Whole Again By Solving Yet Another Desperate Shortage

    Los Angeles, CA.  August 3, 2020 – US Nuclear Corp. (OTC: UCLE) aims to combat COVID-19 and help patients and survivors of the virus by working together with MIFTEC to produce an unlimited supply of domestic, low-cost medical isotopes.

    The IAEA is supporting more than 121 countries with RT-PCR equipment, which is used to rapidly detect COVID-19 in real-time by a nuclear-derived technique and is one of the most widely used and accurate lab methods. The isotope Co-60 is also being used to sterilize medical equipment, devices, and supplies for COVID-19 professionals to ensure they are safe for use.  Co-60 irradiation is one of the quickest and effective methods for sterilizing large volumes of this equipment.

    Medical isotopes and nuclear medicine are proving to be effective in sterilizing, detecting, and fighting COVID-19 and guiding successful treatment. In addition to damaging the patient’s lungs, this virus also attacks the heart, blood vessels, liver, intestines, brain, and nervous system. It causes blood clots and sometimes strokes or seizures. Unfortunately, as a result, many of our COVID-19 survivors will need serious medical help for months or years to come.

    Medical isotopes are being used for lung diagnostics, determining the extent of the patient’s disease, and mapping the COVID-19 proteins, while others are being researched as a possible treatment for combating severe COVID-19 cases. Medical isotopes are necessary for nuclear medicine diagnostic scans to guide the physician in treating our brave survivors.

    (more…)

  • Help May Be On Its Way: 10% Of Worlds Population Suffers From Pain or Depression

    Help May Be On Its Way: 10% Of Worlds Population Suffers From Pain or Depression US Nuclear and Grapheton Develop Neural Technology

    Los Angeles, CA.  July 14, 2020 – US Nuclear Corp. (OTC: UCLE), working with a start-up company similar to Elon Musk’s ‘Neuralink’, Grapheton, is eager to announce how Grapheton’s neural stimulation technology can help treat chronic pain and depression.  It is estimated that 500 million people suffer chronic pain worldwide, and 300 million people suffer depression worldwide, affecting more people than any other health burden and adding to suicide and drug addiction rates. These symptoms are mentally and financially devastating to the afflicted persons and their families.  In fact, the total US economic burden of major depressive disorder is now estimated to be $210 billion per year*. Chronic pain and depression are extremely complex disorders that are incredibly hard to treat.  Fortunately, deep brain stimulation is proving to be an effective emerging treatment, and Grapheton has made several significant advances and improvements to the technology to make it even more viable.

    Deep brain stimulation involves the surgical implantation of tiny electrodes in your brain that send electrical signals to the areas of your brain where the problems (pain, depression, or movement disorders) originate.  These electrical signals regulate the brain’s activity in that region which can relieve the symptoms.

    Depression treatments can range from medications to lifestyle changes, therapy, or any combination of the above.  Unfortunately, some medications just exacerbate the problem, and some people have treatment-resistant depression. Deep brain stimulation is emerging as an effective treatment solution for chronic and resistant depression and has been reported to improve mood, alleviate depression, and lead to an increase in quality of life.

    (more…)

  • Radiation Plus Brain Sensors?

    TECHNOLOGY: US Nuclear’s unusual strategic investment. via San Fernando Valley Business Journal. usnuclearcorp.com

    By MARK R. MADLER Staff Reporter

    On the surface, the investment by US Nuclear Corp. in a San Diego company that makes components used in machine-brain interface devices might seem an unusual strategic decision.

    After all, the Canoga Park company’s main business is manufacturing radiation detectors for use at nuclear power plants.

    But Chief Executive Robert Goldstein doesn’t see it that way.
    “We consider ourselves in the sensor business and electrodes that go in the brain are sensors,” Goldstein said.

    Read More

  • NASA Report to Congress on Interstellar Space Travel Includes Presentation of US Nuclear Partner Mifti’s “Star Trek” Fusion Propulsion

    NASA Report to Congress on Interstellar Space Travel Includes 36 Page Presentation of US Nuclear Partner Mifti’s “Star Trek” Fusion Propulsion

    Nasa Report To Congress On Interstellar Space Travel

    Los Angeles, CA.  June 16, 2020 – US Nuclear is excited to announce that MIFTI-MIFTEC President and Chief Scientist, Dr. Hafiz Rahman, was invited by NASA to give a presentation on his fusion energy technology at the Tennessee Valley Advanced Interstellar Propulsion Workshop (TVIW) in Wichita, Kansas.  The workshop was requested by Congress with support from TVIW to explore the top technologies that can be used for deep space travel.

    Dr. Rahman’s 36-page presentation titled “Staged Z-Pinch, A Target for Fusion and Possible Source for Interstellar Propulsion” discusses MIFTI’s latest developments.   MIFTI’s fusion generators could become the standard propulsion system for space travel, and also have the potential to provide unlimited, low-cost, clean energy for the earth, moon bases, and planetary colonization.

    Chemical-powered rockets have taken humans to the moon, sent countless missions into earth’s orbit, and have even powered long-range missions inside and outside of our solar systems, such as the Mars rovers and the Voyager probe launched in 1977 which is now in interstellar space. Speeds of almost 20,000 miles per hour seem fast and may have been adequate for traveling to the moon and even some nearby planets, but are far too slow and heavy with fuel to travel to more distant planets or the countless stars surrounding our solar system. Chemical-powered rockets in use today carry tons of fuel. Fully fueled, the 3-stage Atlas V-541 rocket with the spacecraft can weigh 1 million pounds; 80% of that weight is fuel and the superstructure of the first and second stages carry the fuel.

    (more…)

  • US Air Force Mach2 Code Tests US Nuclear and Mifti Progress of Producing Medical Isotopes

    US Air Force Mach2 Code Tests US Nuclear and Mifti Progress Towards Goals of Producing Medical Isotopes and Electric Power

    Los Angeles, CA.  May 12, 2020 – US Nuclear Corp. (OTC: UCLE) is excited about MIFTI’s (Magneto-Inertial Fusion Technologies, Inc.) recent progress in harnessing clean fusion energy as presented by a new article in a leading peer-reviewed fusion energy journal, AIP Physics of Plasmas.

    Below are some of the steps along the way towards producing clean, no-carbon fusion energy and medical isotopes:

      • August 2018: MIFTI Reaction Cell generates a record 10 billion neutrons per pulse on the 1 million ampere Zebra machine at the University of Nevada, Reno National Terawatt Facility (UNR/NTF) using their patented Staged Z-pinch (SZP) technology.
      • The US Air Force MACH-2 simulation code predicts that US Nuclear partners are likely to achieve 1 trillion neutrons per pulse or better on the L3 Harris 4 million ampere machine; the amount required for commercial production of radioisotopes and possibly to produce enough energy to achieve “Break Even” which is the gateway requirement for electric power production.
      • The year 2020: Plans are now underway to scale-up power for MIFTI and sister company, MIFTEC Laboratories, Inc. (for radiopharmaceuticals). Experiments on L3 Harris’s more powerful 4 million ampere devices are planned to begin this year.
      • It all comes together: MIFTI/MIFTEC have already drawn up the plans for their 10 million ampere machine, which is designed to provide significant net energy gain for the production of power and medical isotopes
      • MIFTI’s SZP thermonuclear fusion energy technology is fueled by a simple isotope of hydrogen from seawater; an environmentally safe, low-cost process for an unlimited, non-proliferating energy source.

    (more…)

  • US Nuclear & Grapheton Provide Significant Advances for Parkinson’s Disease Therapy

    US Nuclear & Grapheton Provide Significant Advances for Parkinson’s Disease Therapy

    Los Angeles, CA.  March 17, 2020 – The next chapter in US Nuclear’s (OTC: UCLE) brain-machine interface revolution in treating Parkinson’s Disease. Over 10 million people live with Parkinson’s Disease worldwide.  Parkinson’s Disease is a degenerative, progressive nervous system disorder that affects nerve cells in deep parts of the brain that control movement and memory. These nerve cells become impaired and/or die, thereby producing less dopamine thus ultimately causing the symptoms of Parkinson’s Disease. These symptoms include: tremors or shaking in your limbs, slowed movement, rigid muscles, impaired balance, coordination, and eventually, profound memory loss and dementia. Fortunately, advances in neurostimulation therapy, such as those made by Grapheton, have made it possible to treat this terrible disease.

    The treatment is called ‘Deep Brain Stimulation (DBS) and involves the surgical implantation of electrodes in your brain that send electrical signals to the areas responsible for body movement. The electrodes do not damage healthy brain tissue or destroy nerve cells; instead, they produce electrical impulses that regulate the abnormal impulses, including those caused by Parkinson’s.

    (more…)